DrugPatentWatch Database Preview
Patent: 7,745,494
» See Plans and Pricing
Summary for Patent: 7,745,494
| Title: | Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy |
| Abstract: | The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin. |
| Inventor(s): | Perez-Soler; Roman (New York, NY), Ling; Yi-He (Briarwood, NY) |
| Assignee: | Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) |
| Application Number: | 11/886,803 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,745,494
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) | 2025-04-15 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 7,745,494
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006113479 | Start Trial |
| United States of America | 2009209652 | Start Trial |
| United States of America | 2009239952 | Start Trial |
| United States of America | 2010324148 | Start Trial |
| United States of America | 2013225690 | Start Trial |
| United States of America | 8283382 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
